Multiple linear regression on clot lysis time* without (model A) and with a squared and cubic term (model B) for PAI-1
| . | Model A . | Model B . | ||
|---|---|---|---|---|
| β (95% CI) . | R2 . | β (95% CI) . | R2 . | |
| Prothrombin | 0.15 (0.08-0.22) | 0.58 | 0.16 (0.11-0.22) | 0.69 |
| Factor VII | 0.05 (−0.09 to 0.11) | 0.07 (0.02-0.12) | ||
| Factor IX | 0.06 (−0.01 to 0.12) | |||
| Factor X | 0.07 (−0.00 to 0.13) | 0.06 (0.00-0.12) | ||
| Factor XI* | 0.05 (0.01-0.10) | |||
| Protein C | 0.07 (0.00-0.13) | |||
| Antithrombin | −0.05 (−0.11 to 0.00) | |||
| Fibrinogen | 0.08 (0.02-0.14) | 0.10 (0.05-0.15) | ||
| Plasminogen | −0.26 (−0.33 to −0.20) | −0.29 (−0.34 to −0.23) | ||
| α2-antiplasmin | 0.14 (0.09-0.20) | 0.16 (0.11-0.21) | ||
| TAFI | 0.21 (0.15-0.26) | 0.23 (0.18-0.28) | ||
| PAI-1* | 0.49 (0.44-0.54) | 0.28 (0.22-0.35) | ||
| PAI-1 (squared)* | 0.27 (0.22-0.32) | |||
| PAI-1 (cubic)* | 0.22 (0.14-0.29) | |||
| . | Model A . | Model B . | ||
|---|---|---|---|---|
| β (95% CI) . | R2 . | β (95% CI) . | R2 . | |
| Prothrombin | 0.15 (0.08-0.22) | 0.58 | 0.16 (0.11-0.22) | 0.69 |
| Factor VII | 0.05 (−0.09 to 0.11) | 0.07 (0.02-0.12) | ||
| Factor IX | 0.06 (−0.01 to 0.12) | |||
| Factor X | 0.07 (−0.00 to 0.13) | 0.06 (0.00-0.12) | ||
| Factor XI* | 0.05 (0.01-0.10) | |||
| Protein C | 0.07 (0.00-0.13) | |||
| Antithrombin | −0.05 (−0.11 to 0.00) | |||
| Fibrinogen | 0.08 (0.02-0.14) | 0.10 (0.05-0.15) | ||
| Plasminogen | −0.26 (−0.33 to −0.20) | −0.29 (−0.34 to −0.23) | ||
| α2-antiplasmin | 0.14 (0.09-0.20) | 0.16 (0.11-0.21) | ||
| TAFI | 0.21 (0.15-0.26) | 0.23 (0.18-0.28) | ||
| PAI-1* | 0.49 (0.44-0.54) | 0.28 (0.22-0.35) | ||
| PAI-1 (squared)* | 0.27 (0.22-0.32) | |||
| PAI-1 (cubic)* | 0.22 (0.14-0.29) | |||
PAI-1 indicates plasminogen activator inhibitor 1; and TAFI, thrombin activatable fibrinolysis inhibitor.
Clot lysis time, factor XI, and PAI-1 were log-transformed.